Difficulty: Medium
Average Score: 76%
Testbank
A client has been found unresponsive at home for an undetermined period of time. A cerebrovascular accident (CVA) is suspected, and the family is demanding a clot buster be used to restore functioning. The nurse knows that successful use of tissue plasminogen activator (TPA) in a client with CVA requires which factor(s) to be true? Select all that apply.
Correct answer
B,E
Rationale
B: Presence of an ischemic stroke. Successful use of tissue plasminogen activator (TPA) in a client with a suspected cerebrovascular accident (CVA) requires confirmation that the stroke is ischemic, as TPA is specifically designed to dissolve blood clots in cases of ischemic strokes and is contraindicated in hemorrhagic strokes.
A: Symptoms no longer evolving. While stable symptoms may suggest a lower risk of further damage, they are not a requirement for TPA administration, which focuses on the type of stroke rather than the symptom timeline.
C: Used concurrently with heparin therapy. TPA is not used alongside heparin therapy due to the increased risk of bleeding complications, making this option irrelevant to the safe administration of TPA in ischemic strokes.
D: Administered intramuscularly for faster response. TPA is administered intravenously, not intramuscularly, as the latter route can increase the risk of bleeding and is inappropriate for this treatment protocol.
E: Administered within 3 hours of onset of symptoms. While timely administration is critical, the specific requirement for TPA is the confirmation of an ischemic stroke rather than solely the timing of symptom onset.
F: Administered for hemorrhagic strokes. TPA is contraindicated for hemorrhagic strokes, as it can exacerbate bleeding, making this option fundamentally incompatible with the use of TPA in any stroke scenario.
A: Symptoms no longer evolving. While stable symptoms may suggest a lower risk of further damage, they are not a requirement for TPA administration, which focuses on the type of stroke rather than the symptom timeline.
C: Used concurrently with heparin therapy. TPA is not used alongside heparin therapy due to the increased risk of bleeding complications, making this option irrelevant to the safe administration of TPA in ischemic strokes.
D: Administered intramuscularly for faster response. TPA is administered intravenously, not intramuscularly, as the latter route can increase the risk of bleeding and is inappropriate for this treatment protocol.
E: Administered within 3 hours of onset of symptoms. While timely administration is critical, the specific requirement for TPA is the confirmation of an ischemic stroke rather than solely the timing of symptom onset.
F: Administered for hemorrhagic strokes. TPA is contraindicated for hemorrhagic strokes, as it can exacerbate bleeding, making this option fundamentally incompatible with the use of TPA in any stroke scenario.